Caplyta is a brand-name prescription drug used to treat certain mental health conditions. It is a type of drug called an atypical antipsychotic. If a person has a Part D prescription drug plan or a ...

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson‘s Caplyta as an add-on treatment for adults with major depressive disorder. Following the FDA’s Nov. 5 decision ...

Add Yahoo as a preferred source to see more of our stories on Google. People gather next to a logo of Johnson & Johnson at the company’s booth at the 8th China International Import Expo (CIIE) in ...

Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA ® is FDA approved to treat schizophrenia ...

Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced the submission of a supplemental New Drug Application/sNDA to the US FDA for ...

Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration has further expanded the labeling for its atypical antipsychotic Caplyta to approve its use in adults with ...

TITUSVILLE, N.J., Nov. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA ® (lumateperone) as an adjunctive therapy ...

People gather next to a logo of Johnson & Johnson at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov (Reuters) -The ...